H Lee Sweeney

Title: H Lee Sweeney: Innovator in Gene Therapy for Usher Syndrome

Introduction

H Lee Sweeney is a prominent inventor based in Gainesville, FL (US). He has made significant contributions to the field of gene therapy, particularly in the treatment of Usher syndrome, a genetic disorder that affects both hearing and vision. His innovative work has the potential to improve the lives of many individuals suffering from this condition.

Latest Patents

H Lee Sweeney holds a patent for "Dual AAV-MYO7A vectors with improved safety for the treatment of USH1B." This patent discloses compositions and methods for treating diseases of the mammalian eye, specifically complications of the retina associated with Usher syndrome IB (USH1B). Additionally, it addresses methods for treating diseases of the mammalian inner ear, focusing on complications of ear hair cells related to USH1B. The invention provides improved AAV-based, dual vector systems that facilitate the expression of full-length proteins whose coding sequences exceed the packaging capacity of an individual AAV vector. The patent describes modified hybrid dual vector systems that shift the coding sequence for the MY07A tail domain to eliminate the production of truncated MY07A protein. Furthermore, it includes improved, codon-modified hybrid and overlap vector systems that remove putative stop codons and residual sequences in non-coding regions.

Career Highlights

H Lee Sweeney is affiliated with the University of Florida Research Foundation, Incorporated. His work has garnered attention for its innovative approach to addressing genetic disorders. With a focus on advancing gene therapy techniques, he has contributed to the understanding and treatment of complex diseases.

Collaborations

H Lee Sweeney has collaborated with notable colleagues, including Shannon E Boye and Sanford L Boye. These partnerships have enhanced the research and development of therapeutic strategies for Usher syndrome.

Conclusion

H Lee Sweeney's contributions to gene therapy, particularly in the context of Usher syndrome, highlight his role as an innovator in the field. His patent for dual AAV-MYO7A vectors represents a significant advancement in the treatment of genetic disorders.